Sumagen Co., Ltd. is a biotechnology company and a member of Curo Group. Sumagen holds Exclusive License for Dr. Kang, Chil-yong’s HIV/AIDS vaccine development and its commercialization. Sumagen is also holder of a Preferred Bidding Rights for the development and subsequent production and marketing for HCV (Hepatitis C Virus) vaccine and the next generation antibiotics of Dr. Heinrich.
Sumagen’s HIV/AIDS vaccine was approved by USFDA for its IND in December of 2011, which now is on the Phase I human clinical trials in the United States, conducted by world renowned with USFDA’s approval for Clinical Trials on Humans, Sumagen is now in Phase I Clinical Trials, conducted by PPD in the United States. Sumagen’s HIV/AIDS vaccine is also supported for its R&D cost from the HIV/AIDS vaccine development fund, jointly launched by the Bill and Melinda Gates Foundation and the government of Canada.
Sumagen Co., Ltd.
CEO and Representative Director
Mr. Cho, Jung-gee
Dr. Kang, Chil-yong (Professor, Microbiology and Immunology at UWO, Canada)
Dr. Lee, Sang-kyun (former president of Toxicology Center of LG Life Science)
4.3 Billion Korean Won (appx. 4 Million US Dollar)
September 20, 2000
Dongwon B/D 4F, Teheran-ro 77-7 Gangnam-gu, Seoul, Korea
700 Collip circle, suite 118, London, ON N6G4X8, CANADA